Skip Navigation


NDT Advance Access originally published online on April 18, 2007
Nephrology Dialysis Transplantation 2007 22(7):1864-1872; doi:10.1093/ndt/gfm129
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/7/1864    most recent
gfm129v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Podjarny, E.
Right arrow Articles by Bernheim, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Podjarny, E.
Right arrow Articles by Bernheim, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Additive renoprotective effect of candesartan and tetrahydrobiopterin in rats after 5/6 nephrectomy

Eduardo Podjarny1, Joelle Bernheim3, Galit Hasdan1, Dorit Karsh4, Gloria Rashid2, Janice Green2, Bernardo Katz2 and Jacques Bernheim1,2

1Department of Nephrology and Hypertension, 2Laboratory of Renal Physiology, 3Department of Pathology, Sapir Medical Center, Kfar-Saba, Sackler Faculty of Medicine, University of Tel Aviv, Israel and 4Department of Information and Statistics, Clalit Health Services, Israel

Correspondence and offprint requests to: Jacques Bernheim, Dept of Nephrology & Hypertension, Meir Hospital, Kfar Saba, 44281 Israel. Email: podjarny{at}post.tau.ac.il



  Abstract

Background. Chronic treatment with candesartan cilexetil (C) improves the outcome of rats after 5/6 nephrectomy (Nx). Tetrahydrobiopterin (BH4), an essential cofactor for appropriate endothelial nitric oxide synthase (eNOS) activity, prevents an increase in blood pressure (BP) in Nx rats when given immediately after surgery. In the present study, we evaluated the renoprotective effect of a combined treatment.

Methods. Five groups of rats were studied: SHAM (sham-operated rats, n = 12); SNx (untreated 5/6 nephrectomized rats, n = 15); C (SNx rats treated with candesartan cilexetil, 5 mg/kg/day per os, n = 11); C + BH4 (SNx rats treated with candesartan cilexetil and BH4, 10 mg/kg/day intraperitoneally, n = 11); and BH4 (SNx rats treated with BH4, 10 mg/kg/day intraperitoneally, n = 11). Treatment began 30 days after surgery, when hypertension and renal insufficiency have developed. This day was considered as day 1 of treatment for statistical comparisons. The study was continued until 50% mortality was achieved in the SNx rats (4 months after surgery).

Results. The survival rates were 100% for SHAM, 47% for SNx, 50% for BH4, 64% for C and 80% for C + BH4 (P < 0.05 vs all). Untreated Nx rats developed hypertension, proteinuria (UP) and severe renal insufficiency. Mortality was associated with a lower renal function and increased urine protein excretion. In C and C + BH4 rats, systolic blood pressure (SBP) decreased significantly. BH4 alone had a mild non-significant effect on SBP.

C and C + BH4 treatments attenuated significantly the increase in proteinuria found in SNx animals.

The weight of the remnant kidneys as well as the severity of glomerulosclerosis were significantly lower in the C + BH4 rats.

Conclusion. This study shows that in subnephrectomized rats, addition of BH4 to a treatment with candesartan had an additive renoprotective effect. The mechanism of such action may include a better control of BP associated with a blockade of actions of angiotensin II (Ag II), an improvement in nitric oxide synthesis and a balanced redox.

Keywords: angiotensin receptor antagonist; hypertension; nitric oxide; proteinuria; renal failure; tetrahydrobiopterin

Received for publication: 15. 4.06
Accepted in revised form: 14. 2.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.